Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
MedPage Today on MSN2d
Alzheimer's Research Funds in Limbo; X Chromosome and the Brain; Stress and StrokeTris Pharma announced positive topline results from the ALLEVIATE-2 phase III clinical trial of investigational cebranopadol to treat moderate-to-severe acute pain after bunionectomy surgery. Axonal ...
Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.
BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...
Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down ...
After hours: March 7 at 4:13:42 p.m. EST Loading Chart for DNLI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback